Shares of Pulse Biosciences, Inc. (NASDAQ:PLSE - Get Free Report) were down 2.9% on Friday . The stock traded as low as $16.68 and last traded at $16.50. Approximately 87,431 shares were traded during mid-day trading, a decline of 42% from the average daily volume of 150,826 shares. The stock had previously closed at $16.99.
Analyst Ratings Changes
Separately, StockNews.com raised Pulse Biosciences to a "sell" rating in a research note on Thursday, January 2nd.
View Our Latest Report on PLSE
Pulse Biosciences Price Performance
The firm has a 50 day moving average price of $19.16 and a two-hundred day moving average price of $18.26.
Institutional Investors Weigh In On Pulse Biosciences
Several institutional investors and hedge funds have recently made changes to their positions in the business. Vanguard Group Inc. boosted its position in shares of Pulse Biosciences by 15.1% during the 4th quarter. Vanguard Group Inc. now owns 1,146,339 shares of the company's stock valued at $19,958,000 after purchasing an additional 150,506 shares in the last quarter. Bank of America Corp DE increased its holdings in shares of Pulse Biosciences by 0.4% during the fourth quarter. Bank of America Corp DE now owns 788,454 shares of the company's stock valued at $13,727,000 after acquiring an additional 2,884 shares in the last quarter. State Street Corp increased its holdings in shares of Pulse Biosciences by 17.8% during the third quarter. State Street Corp now owns 461,333 shares of the company's stock valued at $8,092,000 after acquiring an additional 69,696 shares in the last quarter. Geode Capital Management LLC increased its holdings in shares of Pulse Biosciences by 0.8% during the fourth quarter. Geode Capital Management LLC now owns 460,768 shares of the company's stock valued at $8,024,000 after acquiring an additional 3,603 shares in the last quarter. Finally, Invesco Ltd. increased its holdings in shares of Pulse Biosciences by 1,956.7% during the fourth quarter. Invesco Ltd. now owns 214,490 shares of the company's stock valued at $3,734,000 after acquiring an additional 204,061 shares in the last quarter. Institutional investors own 76.95% of the company's stock.
About Pulse Biosciences
(
Get Free Report)
Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.
Further Reading
Before you consider Pulse Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pulse Biosciences wasn't on the list.
While Pulse Biosciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
